Literature DB >> 7908951

Benign intracranial hypertension associated with the withdrawal of a non-ergot dopamine agonist.

S L Atkin1, E A Masson, L D Blumhardt, M C White.   

Abstract

The cases are reported of two patients who developed benign intracranial hypertension after the withdrawal of the novel non-ergot derived dopamine agonist CV 205 502 (quinagolide).

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7908951      PMCID： PMC1072832          DOI： 10.1136/jnnp.57.3.371

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  7 in total

1.  Idiopathic intracranial hypertension.

Authors:  Z Tessler; M Marcus
Journal:  Compr Ther       Date:  1991-01

2.  Bromocriptine in migraine.

Authors:  J M Hockaday; K M Peet; T D Hockaday
Journal:  Headache       Date:  1976-07       Impact factor: 5.887

3.  Pseudotumor cerebri and pregnancy.

Authors:  V L Katz; R Peterson; R C Cefalo
Journal:  Am J Perinatol       Date:  1989-10       Impact factor: 1.862

4.  Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

Authors:  C B Newman; A M Hurley; D L Kleinberg
Journal:  Clin Endocrinol (Oxf)       Date:  1989-10       Impact factor: 3.478

5.  Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.

Authors:  P S Barnett; E Palazidou; J P Miell; P B Coskeran; J Butler; J M Dawson; J Maccabe; A M McGregor
Journal:  Q J Med       Date:  1991-11

6.  Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine.

Authors:  M Fanciullacci; S Michelacci; C Curradi; F Sicuteri
Journal:  Headache       Date:  1980-03       Impact factor: 5.887

Review 7.  Drugs five years later. Bromocriptine.

Authors:  M L Vance; W S Evans; M O Thorner
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.